Fibromyalgia Treatments

LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy, Management of postherpetic neuralgia, Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older, Management of fibromyalgia, Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for:, Neuropathic pain associated with diabetic peripheral neuropathy (DPN) ( 1 ), Postherpetic neuralgia (PHN) ( 1 ), Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older ( 1 ), Fibromyalgia ( 1 ), Neuropathic pain associated with spinal cord injury ( 1 )

SAVELLA is indicated for the management of fibromyalgia. SAVELLA is not approved for use in pediatric patients [see Use in Specific Populations.

AMRIX ® (cyclobenzaprine hydrochloride extended-release capsules) is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. Limitations of Use: AMRIX should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. AMRIX has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy. AMRIX is a muscle relaxant indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. ( 1 ) Limitations of Use: AMRIX should be used only for short periods (up to 2 or 3 weeks) ( 1 ) AMRIX has not been found effective in the treatment of spasticity or cerebral palsy.

FETZIMA ® is indicated for the treatment of major depressive disorder (MDD) in adults. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established. FETZIMA is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) in adults ( 1 ). Limitation of Use : FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established ( 1 ).